Skip to main content

Deschatelets Pascal's Form 4 filing

Apellis Pharmaceuticals, Inc. (APLS) · filed May 9, 2024

Accession no.
0001127602-24-014811
Filed
May 9, 2024
Trade date
May 8, 2024
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.34M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Deschatelets PascalCIK 0001657720Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 8, 2024Common StockMOption exerciseAcquired+78,907$4.31+$340,089.171,194,890Direct
May 8, 2024Common StockSSaleDisposed−56,335$42.15−$2,374,520.251,138,555Direct
May 8, 2024Common StockSSaleDisposed−22,472$42.85−$962,925.21,116,083Direct
May 8, 2024Common StockSSaleDisposed−100$44.03−$4,4031,115,983Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 8, 2024Common StockMOption exerciseDisposed−78,907$0.00$0108,622Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)